[
  {
    "ts": null,
    "headline": "Abbott Laboratories Stock Sees RS Rating Rise To 82",
    "summary": "On Thursday, Abbott Laboratories stock earned a positive adjustment to its Relative Strength (RS) Rating, from 78 to 82. The medical device firm recently announced a collaboration with Tandem Diabetes Care to develop automated insulin delivery systems using a dual glucose-ketone sensor.",
    "url": "https://finnhub.io/api/news?id=953c93f85ce89b9a6e810793785b948c232788a1ec6dc7a91974d93b24f20541",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749751941,
      "headline": "Abbott Laboratories Stock Sees RS Rating Rise To 82",
      "id": 135222818,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "On Thursday, Abbott Laboratories stock earned a positive adjustment to its Relative Strength (RS) Rating, from 78 to 82. The medical device firm recently announced a collaboration with Tandem Diabetes Care to develop automated insulin delivery systems using a dual glucose-ketone sensor.",
      "url": "https://finnhub.io/api/news?id=953c93f85ce89b9a6e810793785b948c232788a1ec6dc7a91974d93b24f20541"
    }
  },
  {
    "ts": null,
    "headline": "PGIM Jennison Health Sciences Fund Q1 2025 Commentary",
    "summary": "The PGIM Jennison Health Sciences Fund lost value, underperforming its benchmark Index during the Q1 of 2025. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=61de796fc57a2eb31c888e46c0ee8624c4c0196c23f4d21c9936f0ecdc480f65",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749723000,
      "headline": "PGIM Jennison Health Sciences Fund Q1 2025 Commentary",
      "id": 135212712,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186875447/image_186875447.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The PGIM Jennison Health Sciences Fund lost value, underperforming its benchmark Index during the Q1 of 2025. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=61de796fc57a2eb31c888e46c0ee8624c4c0196c23f4d21c9936f0ecdc480f65"
    }
  },
  {
    "ts": null,
    "headline": "Promising Results Of Amylin Analogs In Obesity: Metsera Case Review",
    "summary": "Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout potential. Read why MTSR stock is a hold.",
    "url": "https://finnhub.io/api/news?id=71d50c988c5f20bcf0eb28ebc0c4953f5042eb6bce61d724548b6e99609f0c04",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749722610,
      "headline": "Promising Results Of Amylin Analogs In Obesity: Metsera Case Review",
      "id": 135212610,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158974218/image_2158974218.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout potential. Read why MTSR stock is a hold.",
      "url": "https://finnhub.io/api/news?id=71d50c988c5f20bcf0eb28ebc0c4953f5042eb6bce61d724548b6e99609f0c04"
    }
  },
  {
    "ts": null,
    "headline": "Understanding XLV: A Sector ETF Focused On U.S. Healthcare Giants",
    "summary": "The Healthcare Select Sector SPDR Fund ETF is a sector ETF offering exposure to large-cap U.S. healthcare companies. Learn more about XLV here.",
    "url": "https://finnhub.io/api/news?id=3395881387b067938f0ba799e92a4638be4c4545682cad63079c09828b6b9e0b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749722400,
      "headline": "Understanding XLV: A Sector ETF Focused On U.S. Healthcare Giants",
      "id": 135212617,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1432883724/image_1432883724.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Healthcare Select Sector SPDR Fund ETF is a sector ETF offering exposure to large-cap U.S. healthcare companies. Learn more about XLV here.",
      "url": "https://finnhub.io/api/news?id=3395881387b067938f0ba799e92a4638be4c4545682cad63079c09828b6b9e0b"
    }
  },
  {
    "ts": null,
    "headline": "Trump Wants Cheaper Drugs Like Europe Has. How It Works.",
    "summary": "Trump Wants Cheaper Drugs Like Europe Has. How It Works.",
    "url": "https://finnhub.io/api/news?id=9f698653c1a2df4372c8b3a698e0dd3936c283e60cbe2c806d4d889e2bd8eafd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749720060,
      "headline": "Trump Wants Cheaper Drugs Like Europe Has. How It Works.",
      "id": 135214300,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Trump Wants Cheaper Drugs Like Europe Has. How It Works.",
      "url": "https://finnhub.io/api/news?id=9f698653c1a2df4372c8b3a698e0dd3936c283e60cbe2c806d4d889e2bd8eafd"
    }
  },
  {
    "ts": null,
    "headline": "India's OneSource eyes weight-loss drug boost to order book",
    "summary": "Indian contract drug manufacturerOneSource Specialty Pharma expects strong growth inits order book over the next three years, driven by the globalboom in weight-loss drugs, its top executive said...",
    "url": "https://finnhub.io/api/news?id=48b42087f9684301cfe5a8ad880e03a29ea2b4f5aff22ba8de6fc9f17e4880ea",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749712822,
      "headline": "India's OneSource eyes weight-loss drug boost to order book",
      "id": 135211086,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Indian contract drug manufacturerOneSource Specialty Pharma expects strong growth inits order book over the next three years, driven by the globalboom in weight-loss drugs, its top executive said...",
      "url": "https://finnhub.io/api/news?id=48b42087f9684301cfe5a8ad880e03a29ea2b4f5aff22ba8de6fc9f17e4880ea"
    }
  }
]